| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:50 UTC |
|---|
| Update Date | 2022-03-07 02:51:46 UTC |
|---|
| HMDB ID | HMDB0014878 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Riluzole |
|---|
| Description | Riluzole, also known as rilutek, belongs to the class of organic compounds known as benzothiazoles. These are organic compounds containing a benzene fused to a thiazole ring (a five-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom). Riluzole is a medication used to treat amyotrophic lateral sclerosis. However, the action of riluzole on glutamate receptors has been controversial, as no binding of the drug to any known sites has been shown for them. Riluzole is a drug which is used for the treatment of amyotrophic lateral sclerosis (als, lou gehrig's disease). A reformulation of riluzole that originated at Yale University and is known by the code name BHV-0223 is under development for the treatment of generalized anxiety disorder and mood disorders now by Biohaven Pharmaceuticals. Riluzole is a strong basic compound (based on its pKa). CYP1A2 substrates, inhibitors and inducers would probably interact with riluzole, due its dependency on this cytochrome for metabolism. Riluzole is a potentially toxic compound. Very common (>10% frequency): nausea; weakness; decreased lung functionCommon (1–10% frequency): headache; dizziness; drowsiness; vomiting; abdominal pain; increased aminotransferasesUncommon (0.1-1% frequency): pancreatitis; interstitial lung diseaseRare (<0.1% frequency): neutropenia; allergic reaction (including angiooedema, anaphylactoid reaction)Symptoms of overdose include: neurological and psychiatric symptoms, acute toxic encephalopathy with stupor, coma and methemoglobinemia. A Cochrane Library review states a 9% gain in the probability of surviving one year. In addition, as its antiglutamatergic action is still detectable in the presence of sodium channel blockers, it is also uncertain whether or not it acts via this way. |
|---|
| Structure | NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2 InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13) |
|---|
| Synonyms | | Value | Source |
|---|
| Rilutek | Kegg | | Riluzole impax brand | HMDB | | 2 Amino 6 trifluoromethoxybenzothiazole | HMDB | | 2-Amino-6-trifluoromethoxybenzothiazole | HMDB | | Aventis brand OF riluzole | HMDB | | Riluzole aventis brand | HMDB | | Impax brand OF riluzole | HMDB | | Rhone-poulenc rorer brand OF riluzole | HMDB | | Aventis behring brand OF riluzole | HMDB | | Rhone poulenc rorer brand OF riluzole | HMDB |
|
|---|
| Chemical Formula | C8H5F3N2OS |
|---|
| Average Molecular Weight | 234.198 |
|---|
| Monoisotopic Molecular Weight | 234.007468097 |
|---|
| IUPAC Name | 6-(trifluoromethoxy)-1,3-benzothiazol-2-amine |
|---|
| Traditional Name | riluzole |
|---|
| CAS Registry Number | 1744-22-5 |
|---|
| SMILES | NC1=NC2=C(S1)C=C(OC(F)(F)F)C=C2 |
|---|
| InChI Identifier | InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13) |
|---|
| InChI Key | FTALBRSUTCGOEG-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as benzothiazoles. These are organic compounds containing a benzene fused to a thiazole ring (a five-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom). |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Benzothiazoles |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Benzothiazoles |
|---|
| Alternative Parents | |
|---|
| Substituents | - 1,3-benzothiazole
- Benzenoid
- 1,3-thiazol-2-amine
- Azole
- Thiazole
- Heteroaromatic compound
- Trihalomethane
- Azacycle
- Amine
- Organopnictogen compound
- Organic oxygen compound
- Alkyl halide
- Primary amine
- Organooxygen compound
- Organonitrogen compound
- Organofluoride
- Organohalogen compound
- Organic nitrogen compound
- Alkyl fluoride
- Hydrocarbon derivative
- Halomethane
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 119 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.04 g/L | Not Available | | LogP | 2.3 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 4.9 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 11.6701 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 0.96 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 68.1 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 1523.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 403.5 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 127.4 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 262.9 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 221.7 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 357.1 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 738.8 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 95.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 859.7 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 308.6 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1026.8 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 356.5 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 423.8 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 361.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 102.0 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 47.3 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Riluzole,1TMS,isomer #1 | C[Si](C)(C)NC1=NC2=CC=C(OC(F)(F)F)C=C2S1 | 1646.6 | Semi standard non polar | 33892256 | | Riluzole,1TMS,isomer #1 | C[Si](C)(C)NC1=NC2=CC=C(OC(F)(F)F)C=C2S1 | 1702.0 | Standard non polar | 33892256 | | Riluzole,1TMS,isomer #1 | C[Si](C)(C)NC1=NC2=CC=C(OC(F)(F)F)C=C2S1 | 2100.8 | Standard polar | 33892256 | | Riluzole,2TMS,isomer #1 | C[Si](C)(C)N(C1=NC2=CC=C(OC(F)(F)F)C=C2S1)[Si](C)(C)C | 1681.4 | Semi standard non polar | 33892256 | | Riluzole,2TMS,isomer #1 | C[Si](C)(C)N(C1=NC2=CC=C(OC(F)(F)F)C=C2S1)[Si](C)(C)C | 1845.7 | Standard non polar | 33892256 | | Riluzole,2TMS,isomer #1 | C[Si](C)(C)N(C1=NC2=CC=C(OC(F)(F)F)C=C2S1)[Si](C)(C)C | 1912.0 | Standard polar | 33892256 | | Riluzole,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC2=CC=C(OC(F)(F)F)C=C2S1 | 1839.0 | Semi standard non polar | 33892256 | | Riluzole,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC2=CC=C(OC(F)(F)F)C=C2S1 | 1886.1 | Standard non polar | 33892256 | | Riluzole,1TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)NC1=NC2=CC=C(OC(F)(F)F)C=C2S1 | 2202.2 | Standard polar | 33892256 | | Riluzole,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C1=NC2=CC=C(OC(F)(F)F)C=C2S1)[Si](C)(C)C(C)(C)C | 2047.8 | Semi standard non polar | 33892256 | | Riluzole,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C1=NC2=CC=C(OC(F)(F)F)C=C2S1)[Si](C)(C)C(C)(C)C | 2224.9 | Standard non polar | 33892256 | | Riluzole,2TBDMS,isomer #1 | CC(C)(C)[Si](C)(C)N(C1=NC2=CC=C(OC(F)(F)F)C=C2S1)[Si](C)(C)C(C)(C)C | 2156.2 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Riluzole GC-MS (Non-derivatized) - 70eV, Positive | splash10-00li-2940000000-00c484cbc92e6a94bae0 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Riluzole GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Riluzole GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Riluzole , positive-QTOF | splash10-000i-2590000000-5a9d0f7cdad7e4f2ec6b | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Riluzole , positive-QTOF | splash10-000i-0390000000-4bd44ae3d25f047943e8 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Riluzole , positive-QTOF | splash10-000i-3940000000-1da38288b84e863a64e5 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Riluzole 35V, Positive-QTOF | splash10-000i-0590000000-79d300cfd2b43692d963 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Riluzole 35V, Negative-QTOF | splash10-001i-0190000000-63069bec4e00478eb380 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Riluzole 10V, Positive-QTOF | splash10-000i-0190000000-f0b481a2910122ad9bdc | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Riluzole 20V, Positive-QTOF | splash10-000i-0090000000-d6a855ead1f5f5fe1a37 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Riluzole 40V, Positive-QTOF | splash10-014i-0900000000-b797bc65c27579651949 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Riluzole 10V, Negative-QTOF | splash10-001i-0090000000-4caa5c429c103b56c151 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Riluzole 20V, Negative-QTOF | splash10-001i-0090000000-78bd33541d87ef645303 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Riluzole 40V, Negative-QTOF | splash10-03di-0900000000-6f96de4ddfa58b872d2e | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Riluzole 10V, Positive-QTOF | splash10-000i-0090000000-77cd58803ff632c89002 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Riluzole 20V, Positive-QTOF | splash10-000i-0090000000-77cd58803ff632c89002 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Riluzole 40V, Positive-QTOF | splash10-0a4r-0490000000-ab117c07a1f16bb2d5f8 | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Riluzole 10V, Negative-QTOF | splash10-001i-0090000000-9f868134c3a763fd526e | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Riluzole 20V, Negative-QTOF | splash10-001i-0090000000-9f868134c3a763fd526e | 2021-10-11 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Riluzole 40V, Negative-QTOF | splash10-0a4i-9320000000-2312256d22d9ca57d014 | 2021-10-11 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Song JH, Huang CS, Nagata K, Yeh JZ, Narahashi T: Differential action of riluzole on tetrodotoxin-sensitive and tetrodotoxin-resistant sodium channels. J Pharmacol Exp Ther. 1997 Aug;282(2):707-14. [PubMed:9262334 ]
- Zarate CA Jr, Payne JL, Quiroz J, Sporn J, Denicoff KK, Luckenbaugh D, Charney DS, Manji HK: An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry. 2004 Jan;161(1):171-4. [PubMed:14702270 ]
- van Kan HJ, Groeneveld GJ, Kalmijn S, Spieksma M, van den Berg LH, Guchelaar HJ: Association between CYP1A2 activity and riluzole clearance in patients with amyotrophic lateral sclerosis. Br J Clin Pharmacol. 2005 Mar;59(3):310-3. [PubMed:15752377 ]
- Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH: Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry. 2005 Sep 1;58(5):424-8. [PubMed:15993857 ]
- Mathew SJ, Manji HK, Charney DS: Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92. doi: 10.1038/sj.npp.1301652. Epub 2008 Jan 2. [PubMed:18172433 ]
- Lamanauskas N, Nistri A: Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur J Neurosci. 2008 May;27(10):2501-14. doi: 10.1111/j.1460-9568.2008.06211.x. Epub 2008 Apr 26. [PubMed:18445055 ]
|
|---|